Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
Open Access
- 27 August 2021
- journal article
- research article
- Published by Springer Nature in Schizophrenia
- Vol. 7 (1) , 1-10
Abstract
In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) using a large collection of patient-level data (n = 6685) from randomized controlled trials of risperidone and paliperidone. When analyzing the data by study, we found no material difference in mean effect sizes (ES) between the two measures (PANSS-30 ES = 0.45, PANSS-6 ES = 0.44; p = 0.642). Stratifying the pooled population according to several putative effect moderators (e.g., age, formulation, dose, or diagnosis) generally yielded no meaningful ES differences between the two measures. Similarly, early improvement (≥20% improvement at week 1) on the PANSS-6 predicted subsequent response (≥40% improvement at endpoint) as well as the analog prediction using PANSS-30. Finally, cross-sectional symptom remission assessed via the PANSS-6 showed very good agreement (sensitivity = 100%, specificity = 98%) with cross-sectional symptom remission defined by the Remission in Schizophrenia Working Group.Keywords
Funding Information
- Lundbeck Foundation (R358-2020-2341, R344-2020-1073)
- Novo Nordisk Fonden (NNF20SA0062874)
- Kræftens Bekæmpelse (R283-A16461)
- Det Frie Forskningsråd (7016-00048B)
This publication has 31 references indexed in Scilit:
- Quantifying Clinical Relevance in the Treatment of SchizophreniaClinical Therapeutics, 2011
- Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of SchizophreniaNeuropsychopharmacology, 2009
- Is the antidepressive effect of second-generation antidepressants a myth?Psychological Medicine, 2009
- AN ITEM RESPONSE THEORY ANALYSIS OF THE POSITIVE AND NEGATIVE SYNDROME SCALE: PSYCHOMETRIC RECOMMENDATIONS TO IMPROVE THE APPRAISAL OF SYMPTOM SEVERITYSchizophrenia Research, 2008
- A new self-rating scale for detecting atypical or second-generation antipsychotic side effectsJournal of Psychopharmacology, 2008
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed bookBiological Psychiatry, 2004
- Early Prediction of Antipsychotic Response in SchizophreniaAmerican Journal of Psychiatry, 2003
- A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scaleSchizophrenia Research, 1996
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patientsActa Psychiatrica Scandinavica, 1987